CCCR Weekly Funding Opportunity List

Information courtesy of:

Danika Makowski, PhD - johnstondm [at]

Research Program Manager/Grants Administrator - CCCR


Upcoming Funding Opportunities




AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship – Oct. 30 LOI

The AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship encourages and supports postdoctoral or clinical research fellows to establish a successful career path in cancer research. Research proposed for funding may be in any area of basic cancer research.

This fellowship provides a two-year grant of $120,000 to support the salary and benefits of the fellow while working on a mentored basic cancer research project. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses. CLICK HERE for application instructions.




The Doris Duke Charitable Foundation 2021 Clinical Scientist Development Award – Nov. 13 pre-application

The Clinical Scientist Development Award does not require institutional nomination. This competition employs a two-stage process. Pre-proposal applications will be reviewed and approximately 50 applicants will be invited to submit a full proposal in March. Pre-proposal applications are being sought from physician scientists in their first faculty position conducting clinical research in any disease area. This year, Instructors are eligible to apply. To learn more about this funding opportunity CLICK HERE.


Department of Defense Rare Cancers Research Program (RCRP) – Nov. 30

FY20 Funding Opportunities released: Rare Cancers Research Program (RCRP)

Concept Award
LOI due 11/12/2020, Application due 11/30/2020
Eligibility: Investigators at or above the level of postdoctoral fellow.
1 year/ $100,000

Idea Development Award
LOI due 11/12/2020, Application due 11/30/2020
Eligibility: Investigators at or above the level of Assistant Professor.
3 years/ $350,000

Resource and Community Development Award
LOI due 11/12/2020, Application due 11/30/2020
Eligibility: Investigators at or above the level of Assistant Professor.
3 year/$600,000


CLICK HERE for reference table.
CLICK HERE for more information.





John Hansen Research Grant award – Dec. 8

The John Hansen Research Grant awards €240,000 ($270,000) over a period of three years (maximum €80,000/$90,000 per year). Up to four projects will be selected from among the eligible applications.

RESEARCH SCOPE: The research proposal must address issues on hematopoietic stem cell transplantation or cell therapy. Various aspects can be covered, including but not limited to: diagnostic and therapeutic strategies, transplant immunology, stem cell transplantation complications, donor selection or cell manufacturing.

Applicants must have obtained doctorate, a PhD., MD or equivalent in a field relevant to the award within the last twelve years (plus one year per child for mothers). Applicants do not need to hold a faculty position and can be in training (Fellows, Postdoctoral Fellows and Junior Faculties). CLICK HERE for more information.


ALSF 2021 RUNX1 Early Career Investigator Grant - Dec. 16

The RUNX1 Research Program and Alex’s Lemonade Stand Foundation are delighted to continue their partnership and funding opportunity for early career investigators: the RRP and ALSF RUNX1 Early Career Investigator Program.

Key Objective: To promote the establishment of a new generation of translational and clinical researchers interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder. We believe that providing capital to early career investigators not only injects funding to where it is needed most, but also cultivates a new cohort of investigators who will be invested in an area of research that historically has had limited attention.

Program Description: The RUNX1 Early Career Investigator grant is a 3-year award designed to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with RUNX1- FPD. Collaboration and data sharing are a priority for this research program. The RUNX1 Research Program and ALSF host an annual scientific meeting that brings together grant recipients and other scientists. Grant recipients are expected to present their progress as part of the annual review. A RUNX1 Early Career Investigator Grant is $180,000 over 3 years (maximum $60,000 per year may be requested). CLICK HERE for RFA.


Rising Tide Foundation for Clinical Cancer Research - LOI Dec. 31

The overall goal of Rising Tide’s research funding program is to improve treatment options and quality of life for cancer patients by funding clinical studies focused on prevention, detection, treatments and aftercare. The duration of projects we fund is usually 3 – 5 years. All cancer types are considered. Both new and established investigators are encouraged to apply. We are interested in funding Phase I to Phase III clinical trials. CLICK HERE for RFA.




ASH Funding Opportunities – Jan. 15

The ASH Research Training Award for Fellows is open to both MD and MD-PhD researchers between their second and fifth year of fellowship. The award provides each recipient with $70,000 for a one-year period to guarantee protected time for clinical, basic, or translational research. Additionally, funding is available each year for up to four RTAF recipients to apply for a second year of support.

The ASH Minority Hematology Fellow Award is open to MD/DO, PhD, and MD/DO-PhD researchers in their first or second year of fellowship at the time of application. The award provides each recipient with $100,000 for a two- to three-year period to guarantee protected time for clinical or laboratory-based hematology research projects, to develop additional skills in the conduct of research, and generate preliminary data. Additionally, awardees whose ASH Annual Meeting abstracts are accepted for oral or poster presentation may be eligible for annual meeting hotel and travel benefits.

The ASH Minority Hematology Graduate Award (MHGA). The award provides funding for students conducting research on hematology-focused projects and is open to doctoral students in their first, second, or third year of graduate school at the time of application.

CLICK HERE for more opportunities.

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required) - Jan 25
The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant. CLICK HERE for RFA




NIH NOT-OD-20-097: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences – April 13

This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health. CLICK HERE for Supplement FOA




E.W. "Al" Thrasher Awards

The Thrasher Research Fund has been awarding grants for children's medical research for over 40 years. The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an emphasis on projects that have the potential to translate into clinically meaningful results within a few years. The Fund awards grants two times per year, with no fixed number of awards given in each funding cycle or in each year. The Thrasher Research Fund is open to applications that address a variety of significant pediatric problems. Both incidence and severity are considered when determining the significance of the proposed topic. The Fund supports research both within and outside the United States.

Ideal applications for the E.W. "Al" Thrasher Award address significant health problems that affect children in large numbers and offer the potential for practical solutions to these problems. Such solutions should be innovative and have the potential for broad applicability with low financial and/or technical barriers to implementation. Hypothesis-driven research is preferred over exploratory, hypothesis-generating research. Projects with a shorter distance to clinical applicability are given priority.
Principal Investigators must be qualified in terms of education and experience to conduct research. A doctoral-level degree is required. There are no citizenship or residency requirements. The Fund is open to applications from institutions both inside and outside the United States. You can read more information about the proposal HERE. To view the application form instructions CLICK HERE.


A Kids’ Brain Tumor Cure Foundation

A Kids’ Brain Tumor Cure, a national non-profit organization, was founded in 2007 by a group of dedicated parents, physicians and friends to improve the treatment, quality of life, and long-term outlook for children with brain tumors through research, support, education, and advocacy. The number one priority of A Kids’ Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. Our hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children’s brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered. Investigators in the early years of their careers are encouraged to apply. Find out more here.

Award Description

· Award funding is based on size, impact and complexity of project.

· Funding can be awarded over one, two or three year period.

· Previous PLGA Foundation grant recipients are eligible to apply.

Please email them at contact [at] or call 914-762-3494 with any questions or for further information.

Solving Kid's Cancer

Solving Kids' Cancer is a nonprofit organization with a track-record of funding novel clinical research for children diagnosed with high-risk solid tumors specifically neuroblastoma, brain tumors and sarcomas.

The Therapeutic Development Initiative (TDI) is SKC's strategic platform for the implementation of our research agenda. The TDI's goal is to support innovative early phase clinical studies that are high on the risk/reward spectrum. Priority is given to proposals that introduce novel therapeutic agents and modalities and have a strong potential to improve treatment outcomes.

Key points

· The TDI of SKC only supports clinical research, with focus on novel clinical studies for neuroblastoma, brain tumors and sarcomas.

· Proposals are accepted and reviewed throughout the year on a rolling basis.

· Funding award amounts generally range from $50,000 to $600,000

Submitting a clinical idea of intent to the TDI - guidelines

· Novel investigational agents, combinations, administrations, sequences with strong rationale

· Study protocol to be submitted for IRB approval within 6-months of award

· Study designed to answer hypothesis quickly:

o Phase Ø, Proof-of-Concept, Pilot Study or small Phase I study design

o Enrollment to be completed within two years of IRB approval

· Study will include initial assessment of efficacy of promising therapy

· Correlative component is encouraged

· No institutional overhead or indirect funding will be provided under the terms of the grant

Award Amounts

TDI Awards are funded in a range from $50,000 to $600,000 depending on the nature of the proposed project. No institutional overhead or indirect funding will be provided.

For more information and/or to submit a proposal, email them at: grants [at]

The Alan B. Slifka Foundation Sarcoma Research Grants Initiative

Alan B. Slifka, established this foundation in 1965 to support his passions for “a world safe for difference," Judaism and Israel. In time, his interests expanded to include biomedical research and treatments for sarcoma and other cancers, and autism spectrum disorders. Today, the Alan B. Slifka Foundation board and staff continue to be guided by his passion and generosity. We seek to honor and expand his vision through thoughtful and informed philanthropic strategies.

While any researcher affiliated with a 501(c)(3) may submit a letter of intent at any time, grant applications are received by invitation only. Each application is reviewed on its individual scientific merit in as timely a manner as possible. The peer-review process typically takes 2-4 months.

Grants may be used for the development of models; conducting experiments; development of sarcoma tissue registries; and similar activities related to research into the causes, origins, development, metastasis, molecular biology, diagnosis and treatment of sarcomas. Proposals that pursue studies with patients undergoing treatment or who are participating in an investigational study are considered and have been supported. Grant amounts may vary but generally do not exceed $50,000 for one year. Grant duration also varies but typically does not extend beyond two years. For more information CLICK HERE.


Gateway for Cancer Research

Gateway focuses on transformational science via effective clinical trials—when basic science translates into human testing and clinical practice. We invest in clinical trials to enroll patients at all ages, with all cancer types, whose cancer is at any stage of progress—as long we they have the potential to help people live longer and feel better.
We accept submissions on a rolling basis and typically approve funding requests within 3-4 months—an extraordinarily short timeline compared to most research funding streams. As a result, Investigators can capitalize on Gateway funding to quickly enroll patients and move the research forward more rapidly than most funding allows.
CLICK HERE for more information.